- Home
- MANH vs ROIV Comparison
MANH vs ROIV Comparison
Compare MANH & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MANH
- ROIV
- Stock Information
- Founded
- MANH 1990
- ROIV 2014
- Country
- MANH United States
- ROIV United Kingdom
- Employees
- MANH N/A
- ROIV N/A
- Industry
- MANH Computer Software: Prepackaged Software
- ROIV Biotechnology: Pharmaceutical Preparations
- Sector
- MANH Technology
- ROIV Health Care
- Exchange
- MANH Nasdaq
- ROIV Nasdaq
- Market Cap
- MANH 10.3B
- ROIV 8.4B
- IPO Year
- MANH 1998
- ROIV N/A
- Fundamental
- Price
- MANH $167.52
- ROIV $10.55
- Analyst Decision
- MANH Strong Buy
- ROIV Strong Buy
- Analyst Count
- MANH 10
- ROIV 7
- Target Price
- MANH $266.78
- ROIV $18.08
- AVG Volume (30 Days)
- MANH 1.1M
- ROIV 4.7M
- Earning Date
- MANH 04-22-2025
- ROIV 02-10-2025
- Dividend Yield
- MANH N/A
- ROIV N/A
- EPS Growth
- MANH 24.47
- ROIV N/A
- EPS
- MANH 3.51
- ROIV N/A
- Revenue
- MANH $1,042,352,000.00
- ROIV $122,585,000.00
- Revenue This Year
- MANH $4.28
- ROIV N/A
- Revenue Next Year
- MANH $8.56
- ROIV N/A
- P/E Ratio
- MANH $47.74
- ROIV N/A
- Revenue Growth
- MANH 12.23
- ROIV 140.04
- 52 Week Low
- MANH $164.48
- ROIV $9.76
- 52 Week High
- MANH $312.60
- ROIV $13.06
- Technical
- Relative Strength Index (RSI)
- MANH 28.26
- ROIV 46.48
- Support Level
- MANH $164.48
- ROIV $9.96
- Resistance Level
- MANH $173.55
- ROIV $10.81
- Average True Range (ATR)
- MANH 5.25
- ROIV 0.34
- MACD
- MANH 2.01
- ROIV 0.04
- Stochastic Oscillator
- MANH 13.64
- ROIV 65.92
About MANH Manhattan Associates Inc.
Manhattan Associates Inc provides software that helps users manage their supply chains, inventory, and omnichannel operations. Customers are generally retailers, wholesalers, manufacturers, and logistics providers. The company was founded in 1990 and serves more than 1,200 customers around the world.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.